


End-of-the-year greetings

EHC November 2022 Newsletter

Volunteer with EHC

BioMarin announced an additional serious adverse event in its gene therapy clinical trial for haemophilia A

Meet Jeanette Fava, EHC Operations Director

Update on the Recall of Desmopressin Nasal Sprays
The European Haemophilia Consortium (EHC) would like to update its February 2021 statement concerning the international recall of all Ferring Pharmaceutical Limited nasal sprays containing desmopressin, including Octim®, Octostim®, Desmospray®, DDAVP Spray® and Stimate®....

BioMarin follows up on previously-reported serious adverse event in its phase I/II gene therapy clinical trial for haemophilia A

Pfizer/Sangamo Therapeutics report severe adverse event (SAE) from phase 3 AFFINE haemophilia A gene therapy study
